Table 3.
Most Prevalent Dual Comorbidities and the Dual Comorbidities with Top Polypharmacy Rate
| Most prevalent dual comorbidities among the total enrollees and polypharmacy patients | ||||||||
|---|---|---|---|---|---|---|---|---|
| Total | Polypharmacy | |||||||
| Rank | n (%) | Definition 1 | n (%) | Definition 2 | n (%) | Definition 3 | n (%) | |
| 1 | Hypertension + hyperlipidemia | 7453 (19.4) | Hypertension + diabetes | 5664 (29.1) | Hypertension + diabetes | 2746 (42.9) | Hypertension + diabetes | 6407 (25.8) |
| 2 | Hypertension + diabetes | 7210 (18.8) | Hypertension + hyperlipidemia | 5598 (28.7) | Hypertension + hyperlipidemia | 2345 (36.6) | Hypertension + hyperlipidemia | 6402 (25.7) |
| 3 | Hypertension + depression | 5263 (13.7) | Hypertension + depression | 3957 (20.3) | Hypertension + COPD | 1910 (29.8) | Hypertension + depression | 4662 (18.7) |
| 4 | Diabetes + hyperlipidemia | 4848 (12.7) | Diabetes + hyperlipidemia | 3832 (19.7) | Hypertension + depression | 1906 (29.8) | Diabetes + hyperlipidemia | 4322 (17.4) |
| 5 | Hypertension + COPD | 4406 (11.5) | Hypertension + COPD | 3452 (17.7) | Diabetes + hyperlipidemia | 1865 (29.1) | Hypertension + COPD | 3988 (16.0) |
Definition-1 (new polypharmacy definition) is the simultaneous use of ≥5 different drug classes for a 60-day consecutive period; Definition-2 is the average number of drug classes that was 1 standard deviation above the mean in a 90-day period; Definition-3 is >5 different drug classes used in an arbitrary 90-day period.
COPD, chronic obstructive pulmonary disease.